Full-Time
Manager, Data Engineering & AI Platforms
Data & Intelligence
Updated on 9/9/2026
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
No salary listed
Hyderabad, Telangana, India
Hybrid
Hybrid work in Hyderabad, India.
Bachelor's, Master's
 Engineering Management (1) |
|---|
Get referred to Johnson & Johnson
See people who can refer or advise you
- A bachelor's degree in Computer Science, Engineering, Information Technology, Data Science, Bioinformatics, or a related field is required.
- At least 10 years of experience in Data Engineering, Data Platforms, Analytics, or Artificial Intelligence is required.
- At least 5 years of people leadership experience managing global engineering teams is required.
- Experience delivering enterprise-scale cloud data platforms and modern analytics capabilities is required.
- Proven experience implementing Artificial Intelligence, Machine Learning, and Generative Artificial Intelligence solutions in production environments is required.
- Experience working within Pharmaceutical, Biotechnology, Healthcare, or other regulated industries is required.
- Demonstrated success managing cross-functional stakeholders and global delivery teams is required.
- Experience with Databricks, Apache Spark, Delta Lake, SQL, Python, data modeling, ETL/ELT frameworks, data lakehouse architecture, data product development, AWS, cloud-native data and AI services, Infrastructure as Code, DevOps and CI/CD, Large Language Models, Generative AI, Agentic AI, Retrieval Augmented Generation, vector databases, MLOps, AI governance, Machine Learning Engineering, clinical trial data, clinical data management, CDISC standards including SDTM and ADaM, regulatory data, Medical Affairs data, Safety and Pharmacovigilance, and Real-World Data/Real-World Evidence is required.
- Ensure compliance with GxP, Computer System Validation, HIPAA, GDPR, J&J Data Privacy Standards, and AI Governance requirements.
- Implement and maintain secure, compliant, and auditable platforms within regulated environments.
- Lead the engineering strategy and execution for Clinical Data Platforms supporting Clinical Operations, Data Management, Biostatistics, Medical Affairs, and Regulatory functions.
- Drive modernization of enterprise clinical data ecosystems using cloud-native architectures and Data Product principles.
- Establish reusable clinical data services, ingestion frameworks, and standardized data models.
- Partner with Clinical Development stakeholders to define technology roadmaps and prioritize platform investments.
- Ensure scalability, performance, data quality, security, and operational excellence of clinical data solutions.
- Lead the design and implementation of enterprise-scale Clinical Data Lakehouse solutions using Databricks and modern cloud technologies.
- Build and optimize ETL/ELT pipelines integrating clinical trial management, electronic data capture, ePRO/eCOA, safety and pharmacovigilance, regulatory, real-world, and Medical Affairs data sources.
- Develop reusable clinical data products that enable analytics, reporting, AI, and self-service consumption.
- Drive best practices for data governance, metadata management, lineage, data quality, and interoperability.
- Lead implementation of AI-powered solutions that improve clinical trial efficiency, data review, patient insights, and operational decision-making.
- Develop and operationalize Machine Learning, Predictive Analytics, Generative AI, Agentic AI, Clinical Copilot, Intelligent Automation, and Retrieval Augmented Generation solutions.
- Establish AI governance frameworks aligned with Responsible AI principles and regulatory expectations.
- Partner with Data Scientists and Product Teams to operationalize AI solutions using MLOps best practices.
- Drive AI platform adoption across Clinical Development and R&D functions.
- Lead Agile delivery teams utilizing Product Operating Model principles.
- Collaborate with Clinical Scientists, Data Managers, Biostatistics Teams, Medical Affairs, Regulatory Affairs, Product Managers, and Enterprise Architects.
- Translate complex business and scientific requirements into scalable technology solutions.
- Lead architecture reviews, technical design decisions, project execution, and risk mitigation activities.
- Communicate with executive leadership and business stakeholders.
- Build, develop, and retain high-performing Data Engineering and AI teams.
- Establish engineering excellence practices, technical standards, and career development frameworks.
- Lead workforce planning, vendor management, hiring, and capability development activities.
- Partner with Quality, Compliance, and Security teams to ensure inspection and audit readiness.
- A master's degree is preferred.
- Experience supporting Clinical Development, Clinical Data Management, or Pharmaceutical R&D organizations.
- Databricks, Azure, or AWS certifications.
- Experience building AI-enabled products and data platforms.
- Knowledge of Product Operating Model and Data Mesh principles.
- Experience leading digital transformation initiatives within healthcare or life sciences organizations.
- Experience with Azure.
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
- IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
- Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.
What critics are saying
- The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
- CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
- Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.
What makes Johnson & Johnson unique
- J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
- Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
- Its oncology and immunology franchises offset Stelara’s erosion.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -3%Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.
Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.
Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.
AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.
Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.